Shooting Cancer Highlights: precision oncology in motion. ASCO 2025 edition
Several studies presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting touched on genotyping pharmacogenes linked to anticancer drugs toxixcity. Here, we report on those underscoring the importance of pre-treatment pharmacogenetic testing in order to avoid or reduce adverse drug reactions. DPYD Two abstracts from the Atrium Health Levine Cancer Institute highlight […]
Shooting Cancer Highlights: precision oncology in motion. ASCO 2025 edition
More than half the sessions at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting touched on immunotherapies, cell and gene therapies, and antibody-drug conjugates (ADCs) whereas about 10% of the content was focused on traditional modalities of chemotherapy, radiation, and surgery. Here, we report on data presented at the meeting and coming from […]
Shooting Cancer Highlights – UGT1A1 & DPYD: Safer chemotherapy starts with genotyping
DPYD Genotyping in Fluoropyrimidine Therapy: Reducing Toxicity, Improving Outcome Fluoropyrimidines such as 5-fluorouracil (5-FU), capecitabine, and tegafur are widely used in oncology, treating over 3.5 million patients annually—with 600,000 in Europe alone. Despite their effectiveness, these drugs carry a significant risk of toxicity: 10–40% of patients develop severe side effects (Grade 3–4) requiring hospitalisation and […]
MARCH-APRIL 2025 Shooting Cancer Highlights: Periodic focus on regulatory status of new targeted therapies in oncology
EMA March 11 – Amivantamab – NSCLC EGFR. The European Commission (EC) has approved a Type II variation extension of indication for the anti-EGFR-MET bispecific antibody to include the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions (ex19del) or exon 21 L858R substitution mutations, in combination with […]
JANUARY – FEBRUARY 2025 Shooting Cancer Highlights: Periodic focus on regulatory status of new targeted therapies in oncology
EMA January 9 – Osimertinib – NSCLC EGFR. The European Commission (EC) has approved a Type II variation extension of indication for the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as monotherapy, to include treatment of adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose tumours have EGFR […]
NOVEMBER – DECEMBER 2024 Shooting Cancer Highlights: Periodic focus on regulatory status of new targeted therapies in oncology
EMA December 30 – Lazertinib + amivantamab – NSCLC EGFR. The European Commission (EC) has approved a Type II variation extension of indication for amivantamab (anti-EGFR-MET bispecific antibody), in combination with lazertinib (third-generation EGFR tyrosine kinase inhibitor), for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor […]
AUGUST – OCTOBER 2024 Shooting Cancer Highlights: Periodic focus on regulatory status of new targeted therapies in oncology
EMA August 22 – Amivantamab – NSCLC EGFR. The European Commission (EC) has approved an extension of indication for the anti-EGFR-MET bispecific antibody in combination with carboplatin and pemetrexed, for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions (ex19del) or Exon 21 L858R […]
JUNE – AUGUST 2024 Shooting Cancer Highlights: Periodic focus on regulatory status of new targeted therapies in oncology
EMA June 17 – Capivasertib – BC PIK3CA/AKT1/PTEN. The European Commission (EC) has authorised the marketing of the serine/threonine kinase inhibitor. Capivasertib is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. July 3 – Entrectinib – Solid Tumours NTRK. […]
MAY – JUNE 2024 Shooting Cancer Highlights: Periodic focus on regulatory status of new targeted therapies in oncology
EMA May 28 – Selpercatinib – Solid Tumours RET. The European Commission (EC) has approved the extension of indication for the RET receptor tyrosine kinase inhibitor to include the treatment, in monotherapy, of adults with advanced or metastatic RET fusion-positive solid tumours with disease progression on or after prior systemic therapies or who have no […]
MARCH – APRIL 2024 Shooting Cancer Highlights: Periodic focus on regulatory status of new targeted therapies in oncology
EMA April 23 – Tislelizumab – NSCLC EGFR/ALK. The European Commission (EC) has approved the anti-PD-1 monoclonal antibody, across 3 indications for the first- and second-line treatment of adult patients with non–small cell lung cancer (NSCLC). In particular, tislelizumab, in combination with pemetrexed and platinum?containing chemotherapy, is indicated for the first-line treatment of adult patients […]